Home / Tag Archives: Inflammation (page 2)

Tag Archives: Inflammation

GLP-1s and Hyperuricemia: Could These Drugs Reduce Gout Risk?

Illustration of gout inflammation in a toe with uric acid crystals alongside GLP-1 injection and lab results showing high uric acid levels

The potential link between GLP-1 therapies and gout risk is gaining attention as clinicians look beyond glucose control to broader metabolic outcomes. Patients with obesity and type 2 diabetes often face a dual burden of hyperuricemia and gout, yet these conditions are not always addressed in treatment plans. Could medications …

Read More »

GLP-1s and Microvascular Complications: Do They Change Neuropathy Trajectory?

Physician reviewing digital foot nerve imaging on tablet with GLP-1 injection pen on desk, illustrating microvascular complications and diabetic neuropathy management.

Cardiovascular outcomes often dominate discussions about GLP-1 receptor agonists, but what about nerve health? Growing interest in GLP-1 diabetic neuropathy reflects a broader shift toward understanding microvascular complications beyond heart disease. While medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) have proven cardiovascular benefits, their potential influence on …

Read More »

GLP-1s and Immune Modulation: Exploring Anti-Inflammatory Potential

Medical illustration showing a GLP-1 injection pen, immune cells, inflammatory cytokines, and cardiovascular system highlighting GLP-1 anti-inflammatory effects.

Inflammation sits at the heart of cardiometabolic disease. While GLP-1 receptor agonists are best known for improving glycemic control and supporting weight loss, emerging research suggests their role may extend further. Could the anti-inflammatory effects of GLP-1 therapies help explain some of the cardiovascular benefits observed in large outcome trials? …

Read More »

GLP-1s and the Gut Microbiome: Emerging Insights Into Gut–Metabolic Interactions

Scientific illustration of GLP-1 receptor activity in the intestinal lining surrounded by diverse gut microbiome bacteria, highlighting gut–metabolic interactions.

The conversation around GLP-1 therapies has shifted quickly. While most clinicians focus on weight loss and glucose lowering, new data on GLP-1 microbiome effects suggest something deeper may be happening in the gut. Could these medications reshape the intestinal ecosystem in ways that support long-term metabolic health? Increasingly, researchers believe …

Read More »